Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Summary

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.

Timeline

Start

2025-11-19

Primary completion

2027-08

Completion

2030-01

Drugs

Indications